• COIN
• MSTR
• MU
• NVO

Investing.com’s stocks of the week

This week, Micron and Novo Nordisk faced declines due to disappointing earnings and trial results, while MicroStrategy and Coinbase stock performance fluctuated alongside Bitcoin's price changes.

• BRKa
• COIN
• FDX
• LLY
• NKE
• NVO
• OXY
• TSLA

FedEx, Eli Lilly, Occidental rise premarket; Nike, Novo Nordisk fall

• AMGN
• GPCR
• LLY
• NVO
• VKTX

Viking Therapeutics stock surges 12% amid Novo Nordisk trial woes

• LLY
• NVO

Novo slumps, Lilly gains on trial data results

Novo Nordisk's shares fell 19% after phase 3 trial results for CagriSema, an obesity drug, disappointed. Eli Lilly's stock rose amid growing confidence in its obesity treatments.

• 2070
• LLY
• NVO

In weight loss battle, Novo and Lilly face growing offensive from licensed copies

Novo Nordisk and Eli Lilly face competition from cheaper drug copies abroad, threatening their market share and prompting potential price declines amid rising global obesity rates.

• CTLT
• NVO

Novo Holdings completes $16.5 billion takeover of Catalent

Novo Holdings has acquired Catalent for $16.5 billion, enhancing production capabilities for the popular weight-loss drug Wegovy amid concerns from consumer groups and unions.

• NOVOb
• NVO

EU to review studies linking Novo Nordisk's Ozempic to rare eye condition

The EMA is reviewing studies linking Novo Nordisk's Ozempic diabetes drug to a rare eye condition, although no direct cause-and-effect relationship has been established yet.

• LLY
• NVO

US FDA warns online vendors selling unapproved weight-loss drugs

The FDA issued warning letters to four companies for selling unapproved GLP-1 drugs, indicating misuse of labeling that misled consumers about FDA approval and intended use.

• CTLT
• NVO

Novo Nordisk stock rises following regulatory clearance of Catalent deal

Novo Nordisk shares rose 2% after fulfilling regulatory conditions for its deal with Catalent, indicating a transition to private ownership and enhanced manufacturing capacity.

• CTLT
• DANO
• NVO
• WMT

GLP-1: Barclays on why 2025 could be an inflection point

GLP-1 drugs may transform by 2025, driven by new therapies, increased production, and industry adaptations. Their role in weight loss and potential treatments for other conditions are vital.